Findings come mostly from experimental studies suggesting that KLF2, KLF4, KLF6 and KLF11 act as tumour suppressors in ovarian cancer [13–16] while KLF5, KLF8 and KLF9 might have a potential role in disease development and progression [17–19]. This evidence concerns the gene KLF2 and ovarian carcinoma.